Literature DB >> 29568970

miR‑494‑BAG‑1 axis is involved in cinobufacini‑induced cell proliferation and apoptosis in gastric cancer.

Zhili Shen1, Yan Li2, Chengcheng Zhao3, Fen Wang1, Rongping Zhou1, Gang Chen1.   

Abstract

Cinobufacini is widely used in the treatment of advanced cancers. It has been previously reported that microRNA (miR)‑494 was upregulated in cinobufacini‑treated gastric cancer cells; however, the detailed role of miR‑494 in the anti‑tumor activity of cinobufacini is unclear. The present study aimed to clarify the function of miR‑494 in cinobufacini‑induced cell behavior changes. Cell viability and proliferation ability were investigated using a Cell Counting Kit‑8 assay. Flow cytometry was performed to investigate the apoptosis rate of gastric cancer (GC) cells. The mRNA expression levels of microRNA (miR)‑494 and BCL2 associated athanogene 1 (BAG‑1) were investigated using reverse transcription‑quantitative polymerase chain reaction, and the protein expression level of BAG‑1 was investigated using western blot assays. The results demonstrated that treatment with cinobufacini suppressed proliferation and promoted apoptosis of gastric cancer cells. miR‑494 acts as a tumor suppressor gene in gastric cancer. In cinobufacini‑treated cells, miR‑494 and BAG‑1 exhibited opposing expression trends. Furthermore, knockdown of miR‑494 in cinobufacini‑treated cells upregulated the protein expression level of BAG‑1, promoted cell proliferation and inhibited cell apoptosis. In addition, inhibition of BAG‑1 using small interfering RNA in cinobufacini‑treated cells partially abrogated the effects of miR‑494 inhibitor on cell proliferation and apoptosis. Thus, these results suggest that cinobufacini suppresses GC cells proliferation and promotes apoptosis partially through the regulation of miR‑494‑BAG‑1 axis, which may provide a novel insight into the functional mechanism of cinobufacini.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29568970     DOI: 10.3892/mmr.2018.8788

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  7 in total

1.  Resibufogenin suppresses tumor growth and inhibits glycolysis in ovarian cancer by modulating PIM1.

Authors:  Qian Li; Chuanwu Jiang; Yan Wang; Minghua Wei; Huijin Zheng; Yanqi Xu; Xuegang Xu; Fengyu Jia; Kai Liu; Gang Sun; Jianhua Zang; Ping Mo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-07-10       Impact factor: 3.000

2.  miR-494 promotes progression of retinoblastoma via PTEN through PI3K/AKT signaling pathway.

Authors:  Fen Xu; Guiqin Liu; Lijuan Wang; Xiyan Wang; Xiao Jin; Wen Bo
Journal:  Oncol Lett       Date:  2020-06-17       Impact factor: 2.967

Review 3.  Research Progress in microRNA-Based Therapy for Gastric Cancer.

Authors:  Xu Zhao; Gao-Feng Hu; Yan-Fen Shi; Wei Xu
Journal:  Onco Targets Ther       Date:  2019-12-24       Impact factor: 4.147

4.  Expression of BAG1 is associated with prognosis in kidney renal clear cell carcinoma based on bioinformatics.

Authors:  Hongrong Wu; Minjing Liu; Yuejun He; Guozhao Meng; Wanbei Guo; Qiong Guo
Journal:  BMC Cancer       Date:  2021-02-13       Impact factor: 4.430

5.  Comparative Pharmacokinetics of Cinobufacini Capsule and Injection by UPLC-MS/MS.

Authors:  Ming Li; Yanhong Qin; Zhe Li; Jinshuai Lan; Tong Zhang; Yue Ding
Journal:  Front Pharmacol       Date:  2022-07-18       Impact factor: 5.988

Review 6.  Cinobufacini Injection Improves the Efficacy of Chemotherapy on Advanced Stage Gastric Cancer: A Systemic Review and Meta-Analysis.

Authors:  Xing Zhang; Yuan Yuan; Yupeng Xi; Xinyao Xu; Qiujun Guo; Honggang Zheng; Baojin Hua
Journal:  Evid Based Complement Alternat Med       Date:  2018-09-04       Impact factor: 2.629

7.  Differentially expressed autophagy-related genes are potential prognostic and diagnostic biomarkers in clear-cell renal cell carcinoma.

Authors:  Bangbei Wan; Bo Liu; Gang Yu; Yuan Huang; Cai Lv
Journal:  Aging (Albany NY)       Date:  2019-10-17       Impact factor: 5.682

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.